The primary objective is to measure the prevalence of according to the Frascati classification in a HIV-infected population aged between 55 and 70 years (exposed group) and to compare it with the prevalence of HIV-Associated Neurocognitive Disorders (HAND) in unexposed subjects from the general population-based cohort CONSTANCES, matching subjects on age, gender, geographical origin and socioprofessional category.
Secondary objectives are: * To study factors associated with Asymptomatic Neurocognitive Impairment (ANI) or Mild Neurocognitive Disorders (MND) by distinguishing the impact of traditional risk factors of neurocognitive impairment and those related to HIV infection, * To compare in the exposed and unexposed population physical characteristics, complaints and comorbidities, * To compare global neurocognitive scores in both populations after standardized normal reduction of each test. Methodology: HIV-infected subjects aged between 55 and 70 years will be recruited in centres that support people who living with HIV usually. The study will be proposed consecutively to all subjects aged between 55 and 70 year. A brief inquiry will collect motives on subjects that refuse to participate. A minimum of 70 subjects by 5 years age categories will be included. Unexposed subjects will be recruited in the same regions as their HIV-infected counterparts from the CONSTANCES database, a general population health cohort, after random selection matched on age, gender, geographical origin and socioprofessional category (2 HIV-unexposed subjects for 1 exposed subject). Data collection will follow the same methods as in the CONSTANCES cohort, in particular the neurocognitive tests by trained neuropsychologists.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
220
At the inclusion visit with a self-assessment questionnaire
At the neurocognitive visit, with standard test as CONSTANCES cohort
Standard magnetic resonance imaging
Centre Hospitalier de Cannes - Service de Médecine Interne Oncologie
Cannes, France
Hôpital Michallon- Service des Maladies Infectieuses
Grenoble, France
Hôpial Sainte Marguerite - Service d'hématologie-Cisih
Marseille, France
Hôpital Gui de Chauliac - Service des Maladies Infectieuses
Montpellier, France
Hôpital Carémeau - Service des Maladies Infectieuses
Nîmes, France
Hôpital Bretonneau - Service des Maladies Infectieuses
Tours, France
The Prevalence of Neurocognitive troubles HAND in the HIV-infected and to compare it with the prevalence in the HIV-unexposed population in the CONSTANCES cohort.
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
The prevalence of Asymptomatic Neurocognitive Impairment (ANI)
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
The prevalence of HIV-Associated Dementia(HAD)
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
The prevalence of Mild Neurocognitive Disorder (MND)
Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at month 3 (the neurocognitive visit).
Time frame: at month 3 (neurocognitive evaluation)
Cognitive score distributions untreated or after transformation according to their distribution characteristics
Time frame: at month 3 (neurocognitive evaluation)
Physical score distributions untreated or after transformation according to their distribution characteristics
Time frame: at month 3 (neurocognitive evaluation)
A comparison of a global cognitive score in both populations after standardized normal reduction of each test.
Time frame: at month 3 (neurocognitive evaluation)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.